Loading...
•
Dec 31, 2023
Stoke Therapeutics Q4 2023 Earnings Report
Stoke Therapeutics' financial performance for Q4 2023 was reported, with revenue at $2.8 million and a net loss of $27.0 million.
Key Takeaways
Stoke Therapeutics reported a revenue of $2.8 million and a net loss of $27.0 million for the fourth quarter of 2023. The company's cash, cash equivalents, and marketable securities totaled $201.4 million as of December 31, 2023, anticipated to fund operations to the end of 2025.
Revenue for Q4 2023 was $2.8 million, compared to $3.3 million for the same period in 2022.
Net loss for Q4 2023 was $27.0 million, or $0.60 per share, compared to $25.7 million, or $0.65 per share, for the same period in 2022.
Research and development expenses for Q4 2023 were $21.8 million, compared to $21.1 million for the same period in 2022.
General and administrative expenses for Q4 2023 were $10.6 million, compared to $9.4 million for the same period in 2022.
Revenue by Segment
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...